trial summary · NCT07766187
Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma
Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma (CODAH Trial)
Trial record from the TrialBase DB dataset, status RECRUITING, condition Intrahepatic Cholangiocarcinoma, sponsored by University of Wisconsin, Madison. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The purpose of this research is to evaluate whether adding histotripsy to maintenance durvalumab increases immune response and to assess the safety of this combination for participants with advanced intrahepatic cholangiocarcinoma (iCCA). Histotripsy is a non-invasive, non-thermal treatment that uses focused ultrasound energy to destroy tumor tissue. 12 people will be enrolled in this study.
Source record: https://clinicaltrials.gov/study/NCT07766187
Facts
| registry id | NCT07766187 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Intrahepatic Cholangiocarcinoma |
| sponsor | University of Wisconsin, Madison |
| sponsor class | OTHER |
| enrollment | 12 |
| start date | 2026-11 |
| primary completion | 2032-08 |
| completion | 2032-08 |
| results posted | not reported |
Conditions
- Intrahepatic Cholangiocarcinoma
Interventions
- Histotripsy
- Durvalumab
- Biopsy
Countries
- United States
Intervention types: DEVICE, DRUG, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.